Skip to main content
Eyebright Medical Technology (Beijing) Co., Ltd. logo

Eyebright Medical Technology (Beijing) Co., Ltd. — Investor Relations & Filings

Ticker · 688050 ISIN · CNE1000041J5 LEI · 8368005NTKV08LNSB256 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688050

About Eyebright Medical Technology (Beijing) Co., Ltd.

http://ebmedical.com/en/

Eyebright Medical Technology (Beijing) Co., Ltd. specializes in the research, development, and manufacturing of ophthalmic solutions, focusing on vision correction and cataract surgery. The company's core product portfolio includes high-performance foldable intraocular lenses (IOLs), orthokeratology lenses for myopia management, and ophthalmic viscosurgical devices. By leveraging advanced biomaterial technology and precision engineering, the firm provides clinical solutions for vision restoration and eye health. Its operations encompass the full lifecycle of product development, from material synthesis to clinical application. Eyebright serves a global network of hospitals and eye care professionals, emphasizing technical innovation and quality in the delivery of specialized ophthalmic treatments and diagnostic tools.

Recent filings

Filing Released Lang Actions
688050爱博医疗 2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is titled “2025年度股东会决议公告” and provides detailed voting results for each AGM resolution, including attendance, vote counts, and percentages. It reports official shareholder vote outcomes at the annual general meeting. This matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-21 Chinese
688050爱博医疗 关于职工董事离任及补选职工董事的公告
Board/Management Information Classification · 95% confidence The document is an official announcement by the company’s board regarding the resignation of a board member (employee director Liu Li) and the election of a replacement (Cao Xuehua) – detailing board composition changes, effective dates, and qualifications. This matches the ‘Board/Management Information’ category for changes in the board of directors.
2026-05-21 Chinese
爱博医疗2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled “2025年年度股东会会议资料” and comprises the full set of materials for the company’s annual shareholders meeting: meeting notice, agenda, detailed proposals (board report, profit distribution, annual report approval, auditor appointment, capital changes, etc.), and attachments to be presented and voted on at the AGM. This fits precisely the definition of AGM Information (materials shared at the Annual General Meeting).
2026-05-13 Chinese
爱博医疗董事会薪酬与考核委员会关于公司2021年限制性股票激励计划预留授予部分第四个归属期归属名单的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the verification of the fourth vesting period list of reserved grants under the company's 2021 restricted stock incentive plan. It references relevant laws and regulations about stock incentive plans and confirms the approval of the vesting conditions and submission to the Board for approval. The content focuses on executive compensation and stock incentive plan details, which aligns with remuneration information filings. The document length is short and contains no financial statements or broader management discussion, so it is not an annual or interim report. It is not a proxy solicitation or voting result announcement. Therefore, the document fits best under Remuneration Information (DEF 14A).
2026-04-22 Chinese
爱博医疗2025年度董事会对独立董事独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors assessing the independence of the company's independent directors for the year 2025. It references regulatory requirements related to independent directors and confirms compliance with these rules. The content focuses on governance and board management matters rather than financial results or shareholder voting. The document length is short (472 characters), and it is a formal report on board/management information regarding director independence. Therefore, the most appropriate classification is Board/Management Information (MANG).
2026-04-22 Chinese
688050爱博医疗2025年年度报告
Annual Report Classification · 100% confidence The document is titled "爱博诺德（北京）医疗科技股份有限公司2025 年年度报告" which translates to "Eyebright Medical Technology (Beijing) Co., Ltd. 2025 Annual Report." It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The document length is substantial (15,000 characters) and includes comprehensive financial and operational information for the fiscal year 2025. It also mentions an unqualified audit opinion from the accounting firm, which is typical for an annual report. The presence of detailed quarterly data, financial metrics, and management commentary further confirms this is a full annual report rather than a brief announcement or supplementary document. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.